company background image
FFC

FarmaforceASX:FFC Stock Report

Market Cap

AU$6.7m

7D

0%

1Y

n/a

Updated

19 Oct, 2021

Data

Company Financials
FFC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

FFC Overview

Farmaforce Limited provides contract sales services to the pharmaceutical industry in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Farmaforce
Historical stock prices
Current Share PriceAU$0.051
52 Week HighAU$0.049
52 Week LowAU$0.10
Beta-0.42
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change-57.50%
5 Year Change-68.13%
Change since IPO-84.06%

Recent News & Updates

Shareholder Returns

FFCAU HealthcareAU Market
7D0%-0.2%1.7%
1Yn/a11.0%20.3%

Return vs Industry: Insufficient data to determine how FFC performed against the Australian Healthcare industry.

Return vs Market: Insufficient data to determine how FFC performed against the Australian Market.

Price Volatility

Is FFC's price volatile compared to industry and market?
FFC volatility
FFC Beta-0.42
Industry Beta0.60
Market Beta1

Stable Share Price: Insufficient data to determine FFC's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine FFC's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014n/aGeorge Syrmalishttps://www.farmaforce.com.au

Farmaforce Limited provides contract sales services to the pharmaceutical industry in Australia. The company operates in two segments, Contract Sales and Marketing Services to External Customers; and Services to Related Parties. It also offers sales, data, and medical affairs solutions.

Farmaforce Fundamentals Summary

How do Farmaforce's earnings and revenue compare to its market cap?
FFC fundamental statistics
Market CapAU$6.66m
Earnings (TTM)-AU$980.53k
Revenue (TTM)AU$11.71m

0.6x

P/S Ratio

-6.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FFC income statement (TTM)
RevenueAU$11.71m
Cost of RevenueAU$10.47m
Gross ProfitAU$1.23m
ExpensesAU$2.22m
Earnings-AU$980.53k

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0075
Gross Margin10.55%
Net Profit Margin-8.38%
Debt/Equity Ratio0%

How did FFC perform over the long term?

See historical performance and comparison

Valuation

Is Farmaforce undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: FFC (A$0.05) is trading below our estimate of fair value (A$2.27)

Significantly Below Fair Value: FFC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: FFC is unprofitable, so we can't compare its PE Ratio to the Australian Healthcare industry average.

PE vs Market: FFC is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FFC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FFC has negative assets, so we can't compare its PB Ratio to the AU Healthcare industry average.


Future Growth

How is Farmaforce forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

2.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Farmaforce has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Farmaforce performed over the past 5 years?

31.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FFC is currently unprofitable.

Growing Profit Margin: FFC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FFC is unprofitable, but has reduced losses over the past 5 years at a rate of 31.2% per year.

Accelerating Growth: Unable to compare FFC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FFC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (61.3%).


Return on Equity

High ROE: FFC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Farmaforce's financial position?


Financial Position Analysis

Short Term Liabilities: FFC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: FFC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: FFC is debt free.

Reducing Debt: FFC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable FFC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: FFC is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 60.6% per year.


Dividend

What is Farmaforce current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FFC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FFC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FFC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FFC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FFC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average board tenure


CEO

George Syrmalis (55 yo)

no data

Tenure

AU$95,900

Compensation

Dr. George Syrmalis, M.D., Ph D., FACNP, MAAPP, has been Chief Executive Officer at FarmaForce Limited since November 24, 2015 and has been its Executive Director since November 24, 2015. He has been Chair...


CEO Compensation Analysis

Compensation vs Market: George's total compensation ($USD71.07K) is below average for companies of similar size in the Australian market ($USD301.95K).

Compensation vs Earnings: George's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: FFC's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Farmaforce Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Farmaforce Limited
  • Ticker: FFC
  • Exchange: ASX
  • Founded: 2014
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: AU$6.665m
  • Shares outstanding: 130.68m
  • Website: https://www.farmaforce.com.au

Location

  • Farmaforce Limited
  • 85 Castlereagh Street
  • Level 9
  • Sydney
  • New South Wales
  • 2000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/19 07:02
End of Day Share Price2021/09/08 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.